Lupkynis
Payments companies reported to CMS as associated with Lupkynis. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lupkynis, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lupkynis
These are the largest totals companies reported as associated with Lupkynis. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tina Kochar | Galveston, TX | Nephrology (Internal Medicine) | $179,589.02 |
| German Hernandez | El Paso, TX | Nephrology (Internal Medicine) | $168,423.81 |
| Jorge Larranaga | Kissimmee, FL | Nephrology (Internal Medicine) | $126,109.88 |
| Sreedhara Alla | Shreveport, LA | Nephrology (Internal Medicine) | $96,079.01 |
| Andrew Lazar | Beachwood, OH | Nephrology (Internal Medicine) | $71,967.67 |
| Mohammed Ahmed | Bolingbrook, IL | Nephrology (Internal Medicine) | $69,717.12 |
| Sanjay Chabra | El Paso, TX | Rheumatology | $61,350.52 |
| Dhiman Basu | Colleyville, TX | Rheumatology | $53,940.40 |
| Mohammad Kamgar | Los Angeles, CA | Nephrology (Internal Medicine) | $51,642.36 |
| Abdul Abdellatif | Webster, TX | Nephrology (Internal Medicine) | $51,616.15 |
Prescribed Lupkynis?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.